Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
06/2005
06/16/2005US20050130967 3-Substituted-4-pyrimidone derivatives
06/16/2005US20050130960 (S)-2-(8,9-dihydro-9-methyl-7H-[1,4]oxazino[2,3-g]indazol-1-yl)-1-methylethylamine fumarate for example; 5-HT2 agonists
06/16/2005US20050130956 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof
06/16/2005US20050130943 Bicyclic inhibitors of MEK and methods of use thereof
06/15/2005EP1540382A1 Plastic photochromic lens and method for preparation thereof
06/15/2005EP1539767A2 Opiate analogs selective for the delta-opioid receptor
06/15/2005EP1539766A1 Calcitonin gene related peptide receptor antagonists
06/15/2005EP1539139A2 Compositions and methods for separating amines and amino acids from their counter-enantiomers
06/15/2005EP1539133A1 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity
06/15/2005EP1538907A2 Inhibitors of ftsz and uses thereof
06/15/2005EP1256576B1 Fused imidazolium derivatives
06/15/2005EP1134219B1 Cycloalkyl-substituted aminomethylpyrrolidine derivatives
06/15/2005EP1020451B1 Anilide compounds and drugs containing the same
06/15/2005CN1206230C 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
06/09/2005WO2005052542A2 Method and composition useful for determining fk 506
06/09/2005WO2005051974A2 Novel molecules for regulating cell death
06/09/2005WO2005051958A2 Particle-forming compositions containing fused pyrrolocarbazoles
06/09/2005WO2005051906A2 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051386A1 Hmg-coa reductase inhibitors and method
06/09/2005WO2005051302A2 Bicyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051301A2 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051300A2 Bicyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005016893A3 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
06/09/2005WO2003088897A3 Fab i inhibitors
06/09/2005US20050124646 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
06/09/2005US20050124636 Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
06/09/2005US20050124629 Methods for the purification of levofloxacin
06/09/2005US20050124612 E.g., 2-[2-carboxypropyl]-5-hydroxy-1,2-oxazin-3-one, more potent than desacetoxycephalosporin G; bactericides reacting irreversibly with the active site serine residue of the enzyme; enzyme inhibitors; mimetics; isocephalosporins; monocyclic beta-lactam antibiotics; antibiotic resistance
06/09/2005US20050124607 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
06/09/2005US20050124497 Pesticide, 5-tert-butyl-2-{4-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl]phenyl}-1,3-benzoxazole; chemical intermediates, N-(5-tert-butyl-2-hydroxyphenyl)-4-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl]benzamide; applying on plants, animals
06/09/2005US20050124050 Osteoclast differentiation inhibitors
06/09/2005DE10353300A1 Polyzyklische Makrolactone Polycyclic macrolactones
06/09/2005CA2546486A1 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005CA2546353A1 Bicyclic inhibitors of mek and methods of use thereof
06/09/2005CA2545660A1 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005CA2545659A1 Bicyclic inhibitors of mek
06/09/2005CA2545545A1 Particle-forming compositions containing fused pyrrolocarbazoles
06/08/2005EP1537124A1 C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants
06/08/2005EP1537123A1 Compounds
06/08/2005EP1537122A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
06/08/2005EP1537121A1 Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans
06/08/2005EP1537120A1 Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
06/08/2005EP1537112A1 Condensed pyridines and pyrimidines with tie2 (tek) activity
06/08/2005EP1536789A1 Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
06/08/2005EP1272494B1 Photochromic spiro(indoline)naphthoxazines
06/08/2005EP1015459B1 Tetrazole-containing rapamycin analogs with shortened half-lives
06/07/2005US6903129 D-proline prodrugs
06/02/2005WO2005049735A2 A process for aqueous milling of quinacridone pigments
06/02/2005WO2005049623A1 PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
06/02/2005WO2005049605A1 Antibacterial aminoquinazolidinedione derivatives
06/02/2005WO2005049604A2 Antithrombotic aromatic ethers
06/02/2005WO2005049602A1 Quinolone antibacterial agents
06/02/2005WO2005049585A1 Macrocyclic lactams and pharmaceutical use thereof
06/02/2005US20050119486 Diamine derivatives
06/02/2005US20050119322 Phorboxazole derivatives for treating cancer
06/02/2005US20050119279 Spiro-cyclic compounds useful as anti-inflammatory agents
06/02/2005CA2546620A1 Preparation of 1-aza-2-oxa-dibenzo[e,h]azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
06/02/2005CA2546339A1 Antibacterial aminoquinazolidinedione derivatives
06/02/2005CA2544751A1 Macrocyclic lactams and pharmaceutical use thereof
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1296985B1 Heteropolycyclic inhibitors
06/01/2005EP0909327B1 Erythromycins and process for their preparation
05/2005
05/31/2005US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
05/31/2005US6900224 Effective against a broad range of pathogenic microorganisms with advantages in low susceptibility to microbial resistance, reduced toxicity, and improved pharmacology.
05/31/2005US6900217 Substituted 6,5-hetero-bicyclic derivatives
05/31/2005US6900204 For therapy of bacterial infections
05/26/2005WO2005047295A1 42-o-alkoxyalkyl rapamycin derivatives and compositions comprising same
05/26/2005WO2005047294A1 Macrocyclic kinase inhibitors
05/26/2005WO2005047285A1 Substituted naphthyridinone derivatives
05/26/2005WO2005047252A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
05/26/2005WO2005047245A2 Fluorescence assays with improved blocking groups
05/26/2005US20050113571 Process for preparing maytansinol
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050112778 Method and composition useful for determining FK 506
05/26/2005US20050112693 Screening, biosynthesis of peptides
05/26/2005CA2545055A1 Macrocyclic kinase inhibitors
05/26/2005CA2544191A1 Substituted naphthyridinone derivatives
05/26/2005CA2543627A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
05/26/2005CA2534342A1 Amino acid prodrugs
05/25/2005EP1532155A2 C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS
05/25/2005EP1532137A2 Antimicrobial aza-bicyclic derivates, their compositions and uses
05/25/2005EP1531828A2 Methods of treating bacterial infections and diseases associated therewith
05/25/2005EP1093371B1 Use of fk506 and related macrolides in the manufacture of a medicament for treatment or prevention of pain
05/25/2005CN1620459A 稠合双环嘧啶衍生物 Fused bicyclic pyrimidine derivative
05/25/2005CN1620440A Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
05/25/2005CN1620439A Pancreatic lipase inhibitor compounds, their synthesis and use
05/25/2005CN1203066C (Methylsulfonyl) phenyl-2-(5H)-furanones as cos-2 inhibitors
05/25/2005CN1202864C Use of CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
05/24/2005US6897315 Method for producing 8-methoxy-quinolinecarboxylic acids
05/24/2005US6897310 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction
05/24/2005US6897223 Nitrogen compounds such as Benzyl-8-methyl-5,7-dioxo-1,5,6,7-tetrahydro-(1,2,4)triazolo(1,5-a)pyridine -2-carboxylic acid benzylamide, used for prophylaxis of arthritis, inflammation or cancer
05/24/2005US6897220 Antiproliferative agents
05/24/2005CA2228471C A process for purification of k-252a
05/19/2005WO2005044823A2 Polymorphous forms of rifaximin as antibiotics
05/19/2005WO2005044822A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
05/19/2005WO2005044270A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds
05/19/2005WO2004106492A3 Bicyclicpyrimidones and their use to treat diseases
05/19/2005WO2004050645A8 Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
1 ... 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 ... 220